Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours
10th September 2025 Uncategorised 0
Early data reveals strong response rates in ovarian cancer cohort

More: Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours
Source: News
